This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Dec;105(6):1861; author reply 1861-2.

doi: 10.1213/01.ane.0000287630.15745.d1.

The importance of transparency in industry-sponsored multicenter clinical studies

PMID: 18042896
DOI: 10.1213/01.ane.0000287630.15745.d1

Comment

The importance of transparency in industry-sponsored multicenter clinical studies

Paul F White. Anesth Analg. 2007 Dec.

. 2007 Dec;105(6):1861; author reply 1861-2.

doi: 10.1213/01.ane.0000287630.15745.d1.

Author

PMID: 18042896
DOI: 10.1213/01.ane.0000287630.15745.d1

No abstract available

PubMed Disclaimer

Comment on

A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Gan TJ, Apfel CC, Kovac A, Philip BK, Singla N, Minkowitz H, Habib AS, Knighton J, Carides AD, Zhang H, Horgan KJ, Evans JK, Lawson FC; Aprepitant-PONV Study Group. Gan TJ, et al. Anesth Analg. 2007 May;104(5):1082-9, tables of contents. doi: 10.1213/01.ane.0000263277.35140.a3. Anesth Analg. 2007. PMID: 17456656 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer